SLS

1.83

0.54% -0.01

Handel nachbörslich: 1.82 -0.01 -0.55%

Sellas Life Sciences Group Inc (SLS)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt SLS? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$1.84

Offen:

$1.83

24-Stunden-Volumen:

1.91M

Relative Volume:

0.64

Marktkapitalisierung:

$182.59M

Einnahmen:

Nettoeinkommen (Verlust:

$-37.34M

KGV:

-1.3456

EPS:

-1.36

Netto-Cashflow:

$-36.91M

1W Leistung:

-3.68%

1M Leistung:

+3.39%

6M Leistung:

+81.19%

1J Leistung:

+53.78%

1-Tages-Spanne:

$1.75

$1.88

1-Wochen-Bereich:

$1.75

$1.94

52-Wochen-Spanne:

$0.772

$2.2691

Sellas Life Sciences Group Inc Stock (SLS) Company Profile

Firmenname

Sellas Life Sciences Group Inc

Sektor

Healthcare (1161)

Branche

Biotechnology (651)

Telefon

(646) 200-5278

Adresse

7 TIMES SQUARE, NEW YORK, NY

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

SLS's Discussions on Twitter

Vergleichen Sie SLS mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
SLS Sellas Life Sciences Group Inc	1.83	183.59M	0	-37.34M	-36.91M	-1.36
VRTX Vertex Pharmaceuticals Inc	472.27	120.73B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	564.64	61.80B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	328.00	42.46B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	591.74	35.22B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	296.46	31.99B	3.81B	-644.79M	-669.77M	-6.24

Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2021-07-21	Eingeleitet	Cantor Fitzgerald	Overweight
2018-11-01	Eingeleitet	Oppenheimer	Outperform
2018-04-02	Eingeleitet	H.C. Wainwright	Buy
2018-03-19	Hochstufung	Maxim Group	Hold → Buy

Sellas Life Sciences Group Inc Aktie (SLS) Neueste Nachrichten

Jul 24, 2025

What institutions are buying SELLAS Life Sciences Group Inc. stock nowStrong return on assets - jammulinksnews.com

Jul 24, 2025

Jul 23, 2025

Is SELLAS Life Sciences Group Inc. a good long term investmentTurbocharged investment results - jammulinksnews.com

Jul 23, 2025

What drives USEA stock priceMassive wealth growth - jammulinksnews.com

Jul 23, 2025

Jul 22, 2025

What analysts say about SELLAS Life Sciences Group Inc. stockDynamic capital growth - Autocar Professional

Jul 22, 2025

What drives SELLAS Life Sciences Group Inc. stock priceFree Stock Index Interpretation - jammulinksnews.com

Jul 22, 2025

SELLAS Life Sciences Group Inc. Stock Analysis and ForecastFree Advanced Stock Screener Access - jammulinksnews.com

Jul 22, 2025

Jul 20, 2025

What makes SELLAS Life Sciences Group Inc. stock attractive to long term investorsMomentum Swing Watchlist - beatles.ru

Jul 20, 2025

Jul 18, 2025

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Expected to Rise, Maxim Group Analyst Says - Defense World

Jul 18, 2025

Jul 16, 2025

Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities - Finansavisen

Jul 16, 2025

Sellas Life Sciences shares fall 1.58% premarket after meeting primary endpoints in Phase 2 trial. - AInvest

Jul 16, 2025

SELLAS Meets All Primary Endpoints in Phase 2 Trial of - GlobeNewswire

Jul 16, 2025

Jul 15, 2025

Sellas Targets Tambiciclib To Adverse-Risk Frontline AML Patients After Phase II Success - insights.citeline.com

Jul 15, 2025

What makes SELLAS Life Sciences Group Inc. stock price move sharplyReal Time Breakout Tracking - Newser

Jul 15, 2025

How SELLAS Life Sciences Group Inc. stock performs during market volatilityHigh Yield Opportunities - Newser

Jul 15, 2025

Sellas Flat on Trial Success - Baystreet.ca

Jul 15, 2025

Sellas Life Sciences Meets Primary Endpoints in Mid-Stage SLS009 Trial - MarketScreener

Jul 15, 2025

SELLAS gains on mid-stage trial win for leukemia drug (SLS) - Seeking Alpha

Jul 15, 2025

SELLAS' Phase 2 Study Of SLS009 In Acute Myeloid Leukemia Meets All Primary Goals - Nasdaq

Jul 15, 2025

Why SELLAS Life Sciences Group Inc. stock attracts strong analyst attentionSolid Return Trade Selections - Newser

Jul 15, 2025

SELLAS Life Sciences Group Reports Positive Phase 2 Trial Results for SLS009 in Relapsed/Refractory Acute Myeloid Leukemia - Nasdaq

Jul 15, 2025

SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study - The Manila Times

Jul 15, 2025

Jul 10, 2025

SELLAS Life Sciences Soars 14.21% on Key Appointment - AInvest

Jul 10, 2025

Jul 09, 2025